Objectives-To find whether CSF analysis may differentiate between relapsingrem itting and secondary progressive m ul tiple sclerosis. Methods-In 17 patients with relapsingrem itting and 16 patients with secondary progressive multiple sclerosis, all without current or recent relapses, albumin CSF; peripheral blood ratio, m ononuclear cell number, CD4+, CD8+, and B1+ subsets, CD4+:CD8+ ratio, IgG, IgG index, IgM, IgM index, complement components C3 and C4, and C3 and C4 indices, m yelin basic protein, neuron specific enolase, S I00, and lactate were determ ined. For each measure the statistical distance m easure D 2 was calculated. For com puta tion o f a discriminant score variables with a P value^0 .IS were included (two sided univariate t test). These were albumin CSF: peripheral blood ratio, m ononuclear cell number, IgM, IgM index, C3, C4, neu ron specific enolase, S I00, and lactate.
Multiple sclerosis is a presumed autoimmune disease of the CNS with focal inflammation and demyelination as the major pathological features. The pathogenesis of CNS lesions consists of a series of events. Increased perme ability of the blood-brain barrier enables mononuclear cells to enter the CNS paren chyma and to form perivascular infiltrates.12 The immune mechanisms then occurring involve T cellSj macrophages, and antibodies.1"3 The inflammatory immune attack is thought to result in demyelination.4 Whereas inflamma tion is not necessarily associated with struc tural damage, demyelination leads to persistent deficits, producing a perm anent interruption in axonal conduction.14 Later in the disease proc ess axonal and glial damage also occur. 15 Basically, these processes are reflected by changes in the composition of the CSF. Thus an increased CSF:peripheral blood ratio for albumin represents increased permeability of the blood-brain barrier (transudation), and raised mononuclear cell numbers in CSF reflect the cellular component of the inflammation.* The presence of CSF specific oligoclonal bands and increased IgG and IgM indices indicate intrathecal immunoglobulin production.6 In addition, intrathecal activation of the complement system leads to altered CSF concentrations of the complement com ponents C3 or C4 or their intrathecal synthesis.7 s Increased CSF concentration of myelin basic protein mirrors demyelination Myelin basic protein values are raised in patients with clinically active multiple sclerosis and fall significantly after methylprednisolone treatment.10 N euron specific enolase is a marker for neuronal damage and CSF concen trations are increased in various disorders of the C N S .11"13 The nervous system specific S I00 protein is notably present in astrocytes and oligodendrocytes, and CSF S I 00 is a marker for glial dam age. 11 In patients with multiple sclerosis S 100 concentrations are higher during active disease. 14 15 Subse quently, the CSF lactate concentration in creases as a result of intracerebral processes involving ischaemia.6 17 Most patients with multiple sclerosis start with a relapsing-remitting course. After five to 10 years most patients gradually transgress to the secondary progressive phase.5 H istopathological and M RI evidence indicate that patho genic and pathological differences exist b e tween relapsing-remitting and secondary progressive multiple sclerosis.1819 By contrast with the relapsing-remitting phase the p ro gressive phase shows less evidence for an autoimmune process.5 Data from M R I an d N M R spectroscopy show that the chronic p ro gression is related to neuronal and axonal damage.5 1819 In view of these differences* drugs that are effective in the relapsingremitting phase are not necessarily so in the secondary progressive phase* and drug re search involves separate trials for relapsingremitting and secondary progressive multiple sclerosis. Thus the im m unomodulating agent copolymer-1 has been shown to lessen disabil ity in relapsing-remitting patients but was not effective in the chronic progressive phase,20 21 As the number of immunotherapies is ex pected to increase in the near future* accurate distinction between relapsing-remitting and secondary progressive multiple sclerosis be comes more relevant, to optimise the applica tion of possibly expensive drugs, Importantly* however, at a certain stage of the disease course various circumstances may seriously hinder the differentiation between relapsingremitting and secondary progressive multiple sclerosis-namely* clinical fluctuations in be tween relapses in the relapsing-remitting phase; the insidious character of the transgres sion to the secondary progressive phase; and the occurrence of stable periods in the secondary progressive phase. As a conse quence* in individual patients the secondary progressive phase of the disease can often only be diagnosed reliably in retrospect.
Considering the above* we studied whether detailed CSF examination might differentiate between relapsing-remitting and secondary progressive multiple sclerosis. We measured a range of CSF variables in patients with clinically established relapsing-remitting or secondary progressive multiple sclerosis* and used discriminant analysis to develop an allocation index that distinguishes between the relapsing-remitting and secondary progressive type.
Patients and methods

PATIENTS
Thirty three patients were studied* 17 having been diagnosed as having relapsing-remitting disease and 16 as having secondary progressive disease on clinical grounds* in accordance with a recent consensus report.22 Inclusion criteria were (a) clinically definite multiple sclerosis/ 3 (b) for relapsing-remitting patients: two or more relapses in the preceding two years* and (ic) for secondary progressive patients: at least six months of continuous progression in the year before the study* with or without relapses. Exclusion criteria were (a) relapse in the three months before the study* (6) corticosteroid treatment in the two months before the study* (c) any previous immunosuppressive treat ment* including cyclophosphamide* azathioprine* and cyclosporine A* and (d) contraindi cation for lumbar puncture. In each patient age* disease duration* number of relapses* and total methylprednisolone dose in the two years before the study were ascertained. In second ary progressive patients the duration of the secondary progressive phase was determined. On neurological examination one of us (ORH)* an experienced neurologist* determined the expanded disability status scale (EDSS) score (24) with a 0.5 point interval-based on assessment of the neurological (Kurtzke) and the Scripps neurological rating scales (SNRS) . 24 25 The progression rate was calcu lated as the EDSS score:disease duration ratio. The study protocol was approved by the ethics committee of the University Hospital Ni jmegen. Written informed consent was ob tained from each patient.
CEREBROSPINAL FLUID EXAMINATIONS
Seven types of pathogenic or pathological processes were considered as potentially differ ent between the relapsing-remitting and the secondary progressive phase of the disease: blood-brain barrier disturbance* cellular im mune processes* humoral immune processes* demyelination* neuronal damage* glial damage* and metabolic changes. Measurements in CSF corresponding to these processes were albumin CSF:peripheral blood ratio* mononuclear cell number* CD4+* CD8+* and B1+ subset percentages* CD4+:CD8+ ratio* IgG* IgG index* IgM* IgM index* complement compo nent C3* complement component C3 index* complement component C4* complement component C4 index* myelin basic protein* neuron specific enolase* S100* and lactate. Lumbar punctures were performed at level L5-S1 according to standard procedures with an atraumatic conical elliptic shaped spinal needle 2 2 G 103 mm with introducer (Poly medic). All punctures were performed between 1100 and 1300 hours and about 10 ml colour less CSF was obtained. Simultaneously* pe ripheral venous blood was drawn via cubital venapuncture. Cell counting and determina tion of lymphocyte subpopulations were imme diately performed. For the remaining measure ments paired samples of CSF and serum were stored at -70°C. The lymphocyte subsets were assayed by flow cytometry on a FACS II cell Jongen, Lamers, Doesburg> Lemmens, Hommes For each variable the statistical comparison of the sample distribution between both groups was done by univariate two sample t test (two sided a=0.05). For the computation of an allo cation index (=discriminant score) we tried to use fewer variables. This was achieved by inclusion only of those variables for which the P value of the two sided univariate t test was ^0.15. The simultaneous distributions of these variables were compared between both groups by means of the multivariate r test (Hotelling's test). A discriminant score was computed according to the method of linear discriminant analysis (Fisher's equal probabilities). A sec ond discriminant analysis was performed on those selected variables assumed to be determi nable at routine laboratories. Table 2 shows patient characteristics. As a group secondary progressive patients had significantly higher EDSS scores, lower SNRS scores* and a lower number of relapses than relapsing-remitting patients. All but three patients-one relapsing-remitting and two sec ondary progressive-had received methylprednisolone in the two years before the study, No patient had received prednisone in these years, The total methylprednisolone doses in the two years before the study did not differ signifi cantly between relapsing-remitting and sec ondary progressive patients. Table 1 shows median values of CSF variables, reference values, D 2 after logarithmic transfor- mation> and t test P values. Based on P values the following variables were selected for discriminant analysis: CSF:peripheral blood albumin ratio (P=0.09)j mononuclear cell number (P=0.03)3 IgM (P=0,10)3 IgM index (P=0.15)j complement com ponent C3 (P=0.08)j > complement com ponent C4 (P=0.14)j neuron specific enolase (P=0.12)a S I00 (P=0.13)j and lactate (P=0.08). Discri minant analysis resulted in a discriminant score (allocation index) composed of these nine variables. Using this score all 14 relapsing-remitting patients were allocated to the relapsing-remitting group (positive discri minant score)* and 12 of 13 secondary progressive patients to the secondary progres sive group (negative discriminant score). One secondary progressive patient was allocated to the relapsing-remitting group. Table 3 shows examples of calculation of discriminant scores. Figure 1 shows the discriminant scores for the 33 patients. Notably^ inclusion of nine vari ables by means of a stepwise discriminant analysis (significance levels "entry" and "stay" both 0.15)-in which only patients were included with complete information on all variables-resulted in almost the same set of variables. Only lactate was replaced by myelin basic protein3 probably due to leaving out five patients with missing values on lactate. A sec ond discriminant analysis was performed on those selected variables assumed to be deter minable at routine laboratories. This analysis included only the CSF variables CSF:peripheral blood albumin ratio3 mononuclear cell number, IgM* IgM indexa and lactate. T he scores of the secondary progressive group overlapped those of the relapsing-remitting groups as seven of the 13 secondary progres sive patients had a score falling in the relapsing-remitting range (fig 2 ) . 
Results
PATIENT CHARACTERISTICS
DISCRIMINANT ANALYSIS
D iscu ssio n
Recent reports underline the importance of CSF analysis in the differential diagnosis of CNS disorders.32 33 T he combination of several CSF measurements greatly improves the differ ential diagnosis of multiple sclerosis versus other neurological disorders and CSF analysis supports the diagnostic classification of multi ple sclerosis.23 34 We investigated whether de tailed CSF analysis may differentiate between the relapsing-remitting and secondary progres sive phase of the disease^ and we performed a discriminant analysis of CSF variables in these patients. The variables studied reflected tran-sudation5 cellular and humoral immune proc ess es3 demyelination3 neuronal and glial dam-age3 and hypoxia. The discriminant score allocated 26 out of 27 patients to either the relapsing-remitting or secondary progressive group in agreement with the clinical diagnosis. This finding implies that patients diagnosed as having a relapsing-remitting or secondary pro gressive course on clinical grounds also differ with respect to CSF profile^ and that the discriminant score may be of help in classifying individual patients as being relapsing-remitting or secondary progressive. An important aspect of our study is that we only included relapsing-remitting patients who had had no current or recent clinical relapses. So our data are not confounded by abnormali ties resulting from events related to exacerba tion. On follow up the first exacerbations occurred at a mean of 137 (SD 103) days after Jongen3 Lamerss Doesburg, Lemmens, Hommes CSF sampling, the earliest relapse occurring at 41 days, for which reason it is unlikely that CSF findings reflect a subclinical increase of disease activity.
Pathological and MRI studies in multiple sclerosis suggest that various pathogenic and pathological processes may be at work simultaneously.5 1819 Conceivably, the activity of each of these processes in the secondary progressive phase may be only slightly different from that in the relapsing-remitting phase, which means that for a given variable CSF concentrations in the secondary progressive phase may not differ significantly from those in the relapsing-remitting phase. For this reason we did not search for a single variable that might differerentiate between the two groups; nor did we try to detect significances for single variables. These might be found in large study populations, but, as expected, individual values largely overlap and are of little use as a discriminating tool. By contrast, our study was designed to detect changes in a complex CSF profile in a relatively small group of patients and thus to develop a discrimination index that may be used in individual patients. Thus we found that nine of the 18 variables tested (50%) had a P value ^0.15 and thus contributed to the discrimination index, As CSF measurement of neuron specific enolase, S100, and the complement components C3 and C4 may not be performed routinely in hospital laboratories, we determined the dis criminating value of the CSF:peripheral blood albumin ratio, mononuclear cell number^ IgM, IgM index* and lactate. This second score seemed to be of limited use given that seven of the 13 secondary progressive patients had scores in the relapsing-remitting range.
The establishment of a relation between a clinical variable of multiple sclerosis and changes of CSF mononuclear cells, immu noglobulins or complement components is beset with difficulties, as immunotherapies may have long lasting effects on CSF immune indices. 35 In our study no patient had received any cytotoxic agent, nor had recently used cor ticosteroids. Moreover, the total steroid dose in the two years before the study did not differ between relapsing-remitting and secondary progressive patients. For these reasons we think that we measured intrinsic differences and not treatment induced artifacts.
Generally, the relapsing-remitting patients had increased mononuclear cell numbers and IgM, as well as neuron specific enolase and S 1 0 0 . The results for IgM in these patients seem not to reflect simple blood-brain barrier damage, as the IgM index tended to be higher than in secondary progressive patients. Sec ondary progressive patients generally had increased lactate and albumin with consequent increases of C3 and C4, the last probably due to blood-brain barrier damage rather than local synthesis, as the indices are normal. The significantly lower mononuclear cell numbers in the CSF of secondary progressive patients may indicate that the inflammatory component of the disease "burns out" during its natural course. Our findings on the albumin ratio tend to suggest that damage to the blood-brain bar rier in the secondary progressive phase is rather more diffuse than the more striking punctate abnormalities which are seen in gadolinium MRI studies of the relapsing-remitting form. Others have also shown that the impairment of the blood-brain barrier in secondary progres sive patients is worse than in relapsingremitting patients. 30 For the finding that CSF IgM in secondary progressive patients tended to be lower than in relapsing-remitting patients (means 0,4 ^ 0.6, P = 0.10), Sindic et al reported a raised IgM index in 32% of 80 patients with multiple sclerosis, but in none of 10 patients with a history of multiple sclerosis exceeding 15 years.37 Two other studies registered raised IgM indices at a decreasing rate with an increasing duration of disease.38 39 Although the lower IgM values in our secondary progressive patients may partly relate to duration of disease, the discriminant score was not related to disease duration (data not shown).
Concentrations of C4 in CSF made a large contribution to the differentiation index in that lower C4 is related to the relapsing-remitting course. As early as 1965 it was shown that CSF complement activity is lower in patients with multiple sclerosis than in controls, and die lowest during acute deterioration.40 Moreover, patients with raised C SF y-globulin content showed lower complement activity than those with normal C SF y-globulin, and the comple ment activity was significantly correlated with the total protein concentration in controls, but not in the patients with multiple sclerosis .4Q Recent CSF studies in patients with acute optic neuritis and multiple sclerosis confirmed previ ous reports on intrathecal complement activation.8 Therefore., we think that one expla nation for the relatively low C4 concentrations in our relapsing-remitting group may be steady C4 consumption by immune mediated proc esses in between relapses. On the other handj it is conceivable that C4 discrepancies reflect immunogenetic differences. In a recent study on complement gene polymorphisms Franciotta et al reported that patients with relapsingremitting multiple sclerosis have a significantly higher frequency of C4AQ0 (null) allele than primary progressive patients.41 Moreover, a structural gene deletion was present in 45% of relapsing-remitting patients with the C4AQ0 allele.41 As complement factors contribute to elimination of immune complexes^ deficiency of a functional complement component could predispose to multiple sclerosis, and more spe cifically to the occurrence of virus induced relapses.
The CNS tissue markers S I 00 and neuron specific enolase also contributed to the discri minant score, in that high CSF concentrations suggested relapsing-remitting diagnosis. As our patients were sampled in a relapse free period, this finding suggests that in between relapses tissue damage is more pronounced that in the progressive phase. Recently Massaro et al performed a five week follow up study of CSF changes during and after an exacerbation; S I00 concentrations increased early after relapses and remained increased during the whole study period.15
To conclude^ we calculated a discriminant score that differentiates between relapsingremitting and secondary progressive multiple sclerosis. From a pathogenic and pathophysi ological point of view, our data indicate that a combination of cellular and antibody mediatedj immune processes involving complement lead to damage of neurons and glia3 and that these processes are more pronounced in relapsing-remitting than in secondary progres sive multiple sclerosis. We speculate that moni toring of the discriminant score will prove use ful in the early and accurate diagnosis of the secondary progressive versus the relapsingremitting phase in individual patients. How ever, as we included in our study only patients with an unquestionable clinical course, pro spective studies are needed to validate the dis criminant score and to assess its applicability in patients just transgressing from the relapsingremitting to the secondary progressive phase.
